CVRx AAQS
The The AAQS of CVRx (CVRX) as of Aug 14, 2026 is 3. In the previous year, The AAQS was 3.00 — a change of 0.00% (lower).
Get this data via API
Financial Data API
AAQS
3
YoY
0.00%
Last updated:
CVRx has a current AAQS of 3.
A high AAQS can be seen as a positive indicator that the company is developing successfully.
Investors can assume that the company is on a good path to generate profits.
On the other hand, it is important to consider the AAQS of the stock CVRx in comparison to the profits generated and other companies in the same industry. A high AAQS is not an absolute guarantee for a positive future. Only in this way can one get a complete picture of the company's performance.
In order to better assess the company's development, it is important to consider the AAQS in comparison to other companies in the same industry. In general, investors should always consider the AAQS of a company in connection with other fundamentals such as profit, EBIT, cash flow, and others in order to make an informed investment decision.
A high AAQS can be seen as a positive indicator that the company is developing successfully.
Investors can assume that the company is on a good path to generate profits.
On the other hand, it is important to consider the AAQS of the stock CVRx in comparison to the profits generated and other companies in the same industry. A high AAQS is not an absolute guarantee for a positive future. Only in this way can one get a complete picture of the company's performance.
In order to better assess the company's development, it is important to consider the AAQS in comparison to other companies in the same industry. In general, investors should always consider the AAQS of a company in connection with other fundamentals such as profit, EBIT, cash flow, and others in order to make an informed investment decision.
Access this data via the Eulerpool API
CVRx Stock analysis
What does CVRx do? CVRx Inc is a medical technology company that is revolutionizing the global market for treatment-resistant hypertension patients with its innovative "Baroreflex Activation Therapy" (BAT) system. The company was founded in 2001 and has its headquarters, development, manufacturing, and distribution facility in Minneapolis, Minnesota. With its innovative products and medical expertise, the company aims to become a global leader in medical research and development of apps and medical devices.
The company was founded by Dr. Robert Kieval and his partner in medical research, Dr. Casey Cunningham. Together, they identified a potential treatment gap for patients who were unresponsive to existing methods or unable to receive appropriate therapy due to comorbidities. They decided to develop a novel technology that activates the body's natural regulatory system, the baroreflex system. With a clinical expert team in Minneapolis, they developed an implantable device connected to specific pressure zones in the neck through an electrode. The device artificially stimulates the baroreflex and regulates the blood pressure system. After many years of clinical tests and studies, the company received FDA approval in 2019. The company is now publicly listed, and its products are available worldwide.
CVRx's business model is based on the research, development, production, and marketing of innovative medical devices and technologies. The focus is on improving patients' quality of life and advancing medical research. The products and therapies are distributed globally through contractual partners and subsidiaries. In addition to developing and marketing medical devices, the company conducts research to develop innovative diagnostic and therapeutic methods. The needs of patients and medical research are always the central focus.
CVRx Inc specializes in the development and manufacture of implantable electronic devices for the treatment of patients with chronic cardiovascular diseases. The company's main product is the BAROSTIM NEO System, which is CE-certified in Europe. The system consists of two components: an implanted device and an external remote control. The device is surgically placed below the collarbone, and an electrode is inserted into a carotid artery. The remote control is used to regulate the electrical impulses delivered by the device to the carotid artery, activating the baroreflex system. Clinical studies have shown that BAT therapy is effective in lowering systolic blood pressure in patients with severe and persistent hypertension and can also have positive effects on heart failure patients. The company plans to use the BAROSTIM NEO System for other conditions, such as chronic kidney disease or sleep apnea.
CVRx also invests in the development of mobile applications and software to support data analysis and patient monitoring.
In summary, CVRx Inc is a medical technology company specialized in the development and manufacture of implantable electronic devices. The company is revolutionizing the global market for treatment-resistant hypertension patients with its Baroreflex Activation Therapy (BAT) system. The company focuses on improving patients' quality of life and advancing medical research. In addition to the BAROSTIM NEO System, the company conducts research to develop innovative diagnostic and therapeutic methods. CVRx is one of the most popular companies on Eulerpool.
Frequently Asked Questions about CVRx stock
The AAQS of CVRx is 3 in 2026.
On Eulerpool you can find the complete historical development of The AAQS CVRx since 2006 – with annual values, charts, and detailed analysis.
The AAQS is a key figure developed by AlleAktien.
The AAQS is a key figure developed by AlleAktien.
Access this data via the Eulerpool API
Quality — CVRx
All Key Metrics — CVRx
Valuation
Income Statement
Margins
Balance Sheet
- Total Assets
- Current Assets
- Cash & Equivalents
- Receivables
- Inventory
- Property, Plant & Equipment
- Goodwill
- Intangible Assets
- Equity
- Liabilities
- Debt
- Current Liabilities
- Long-term Debt
- Short-term Debt
- Retained Earnings
- Book Value per Share
- Tangible Book Value per Share
- Working Capital
- Investments
- Accounts Payable
- Non-Current Assets
- Short-Term Investments
- Long-Term Investments
- Net Debt
- Treasury Stock
- Minority Interest
- Deferred Tax Liabilities
- Net Tangible Assets
- Goodwill/Assets
- Intangibles/Assets
Cash Flow
- Operating Cash Flow
- Capital Expenditures
- Free Cash Flow
- FCF per Share
- Dividends Paid
- Share Buybacks
- Investing Cash Flow
- Financing Cash Flow
- CapEx / Revenue
- Cash Flow per Share
- Stock-Based Compensation
- Change in Working Capital
- Acquisitions (Net)
- Net Change in Cash
- CapEx/OCF
- FCF/Net Income
- FCF Conversion
- Cash Conversion
- Total Shareholder Payout
- CapEx/D&A
Profitability
- ROE
- ROA
- ROCE
- ROIC
- Asset Turnover
- Inventory Turnover
- Receivables Turnover
- Days Sales Outstanding
- Days Inventory Outstanding
- Days Payable Outstanding
- Cash Conversion Cycle
- CROIC
- Gross Profit/Assets
- Fixed Asset Turnover
- Equity Turnover
- Working Capital Turnover
- Payables Turnover
- Capital Intensity
- Receivables/Revenue
- Inventory/Revenue
- EBIT/Assets
Leverage
Growth
- Revenue Growth
- Revenue CAGR 3Y
- Revenue CAGR 5Y
- Revenue CAGR 10Y
- Earnings Growth
- EPS Growth
- EBIT Growth
- EBIT CAGR 3Y
- EBIT CAGR 5Y
- EBIT CAGR 10Y
- Dividend Growth
- FCF Growth
- Book Value Growth
- Earnings CAGR 3Y
- Earnings CAGR 5Y
- Earnings CAGR 10Y
- EPS CAGR 3Y
- EPS CAGR 5Y
- EBITDA Growth YoY
- EBITDA CAGR 3Y
- EBITDA CAGR 5Y
- Gross Profit Growth
- OCF Growth YoY
- Employee Growth
- Dividend CAGR 3Y
- Dividend CAGR 5Y
- Dividend CAGR 10Y
- Asset Growth
- Equity Growth
- Debt Growth
- CapEx Growth
- FCF CAGR 3Y
- FCF CAGR 5Y
- Market Cap Growth
- Share Count Growth